With Duaklir nod in EU, AstraZeneca scores first new drug from Almirall buyout

With the EU approval of COPD med Duaklir, AstraZeneca ($AZN) is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement. The LABA/LAMA combo faces rivals from Novartis ($NVS), GlaxoSmithKline ($GSK), and perhaps soon, Boehringer Ingelheim. Report

Read more on